Navigation Links
Lonza Houston Cell and Viral Gene Therapy Manufacturing Facility Wins 2018 ENR Regional Award for Best Project
Date:8/9/2018

CRB is proud to announce that the Lonza Houston Inc. cell and viral gene therapy manufacturing facility has won Engineering News-Record (ENR) Texas & Louisiana’s 2018 Best Projects in the Manufacturing category. A total of 121 entries were submitted for the Best Projects competition. The judges selected 42 projects across 18 categories as the region’s best. Projects were scored on the ability of the project team to overcome challenges, contribution to the industry and community, project innovation, safety and construction/design quality.

CRB’s Dallas office leader, Ashley Frosell, PE, stated, “CRB is extremely proud to be a part of a project that will have such a profound and direct impact on the advancement of revolutionary new cell and gene therapies. We are honored that Lonza trusted our Texas-based team to help translate this initiative into reality.”

Lonza Houston is 300,000-square-foot state-of-the-art facility located on an 11-acre site in Pearland’s Lower Kirby District, just outside Houston, Texas. This project stemmed from the intent to move existing clinical operations out of a location that could no longer support the anticipated operational growth.

CRB provided design-build services to create a 170,000-square-foot greenfield space to house the viral-based cell and gene therapeutics manufacturing operation with an additional 130,000 square feet readily available expansion space to house the anticipated growth of this operation. Clean rooms were designed to manufacture cell therapy and viral gene therapy products to meet the growing demand for products in the U.S. and European markets. Lonza Houston is now the world’s largest dedicated cell and gene therapy manufacturing with process development capabilities bringing products from concept to patient.

"Lonza Houston will serve as a center of excellence for cell and gene therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient," Thomas Fellner, Head of cell & gene therapy at Lonza Pharma & Biotech, said. "This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents."

This project also encountered a formidable challenge halfway through construction that was unlike anything experienced in the area: Hurricane Harvey. Dropping over 40 inches of rain in a four-day period and ultimately causing $125 billion in damage and claiming 88 lives in the region, it was through intense collaboration and teamwork by individuals who had lived and worked through other storms like Hurricane Katrina that the team was able to effectively prepare for and overcome such a significant hurdle.

CRB and Lonza will be recognized at the ENR Texas & Louisiana Best Projects awards ceremony in Houston on October 18, 2018.

About CRB:
CRB is a full-service network of engineers, architects, constructors and consultants assisting advanced technology organizations in the planning, design, construction and operational support of facilities across the globe. With world-class technical expertise and an empowered team of 1,000-plus, we relentlessly pursue and deliver the right solutions to our clients’ technical challenges, no matter how big or small. Since 1984, CRB has earned a reputation for providing value-based solutions, delivering superior quality work and developing long-term partnerships built on trust and productive collaboration. For more information, visit crbusa.com.

About Lonza:
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Founded in 1897 in the Swiss Alps, Lonza today is a well- respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. Further information can be found at lonza.com.

Read the full story at https://www.prweb.com/releases/lonza_houston_cell_and_viral_gene_therapy_manufacturing_facility_wins_2018_enr_regional_award_for_best_project/prweb15680193.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program
2. University of Houston researcher publishes textbook on tissue engineering
3. How much does African dust add to Houstons pollution?
4. Sam Houston State studies DNA preservation in mass disasters
5. University of Houston engineering professor awarded grant to study melanoma treatment
6. Team determines structure of a molecular machine that targets viral DNA for destruction
7. Tiniest catch: University of Arizona scientists fishing expedition reveals viral diversity in the sea
8. Starting signal for antiviral defense
9. Viral infections: Identifying the tell-tale patterns
10. Nanocrystalline cellulose modified into an efficient viral inhibitor
11. Degradation of viral DNA in the cell nucleus is opening up new treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... IRVINE, Calif. (PRWEB) , ... August 06, 2018 ... ... latest evolution of their highly successful business intelligence platform. Inspired by its medical ... streamline the entire user experience on-site. Among the many changes, SmartTRAK 3.0 touts ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... in our Austin office, has been named Practice Group Chair for the Pharmaceuticals ... to help continue growing Dickinson Wright’s healthcare and life sciences initiatives, and appreciate ...
(Date:8/1/2018)... ... ... Dr. Asher Kimchi, Founder and Chairman of the International Academy of ... the 23rd World Congress on Heart Disease held in Boston, MA, USA. In addition ... Fellowship Awards. , Dr. Asher Kimchi, together with Chairman Dr. John A. Elefteriades, headed ...
Breaking Biology News(10 mins):
(Date:8/7/2018)... ... August 06, 2018 , ... PetPace , the makers of a smart ... today announced the launch of a groundbreaking study to identify and eventually predict problems ... study of pregnant dogs sponsored by PetPace and conducted by Dr. Smadar Tal, DVM, ...
(Date:7/31/2018)... ... July 31, 2018 , ... ZeptoMetrix™ Corporation (ZMC) ... its expanding CE/IVD product inventory. , “We are pleased today to introduce two ... remains entirely committed to fully support and provide our diagnostics industry with as ...
(Date:7/26/2018)... ... July 26, 2018 , ... Ariadne ... of a biofield energy treated nutraceutical to improve anti-inflammatory and immune function responses. ... assessed in the preclinical research, were significantly reduced. Results are as follows:, ...
(Date:7/25/2018)... ... 25, 2018 , ... Vium, Inc. http://www.vium.com , the ... Cloud approach to accelerate preclinical drug discovery and development, today announced the promotion ... appointment of Jeff Caron to the newly formed role of Senior Vice President ...
Breaking Biology Technology: